{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Safety+of+Elevated+Doses&page=2", "query": { "condition": "Pharmacokinetics and Safety of Elevated Doses", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 85, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Safety+of+Elevated+Doses&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Safety+of+Elevated+Doses&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T06:03:44.155Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04544436", "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 864, "start_date": "2020-11-26", "completion_date": "2028-02-21", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 25, "location_summary": "Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544436" }, { "nct_id": "NCT03928353", "title": "Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PB2452 Infusion", "type": "DRUG" }, { "name": "Placebo - Sodium Chloride", "type": "DRUG" }, { "name": "Ticagrelor Oral Tablet - Pre-Treatment", "type": "DRUG" }, { "name": "Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SFJ Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 23, "start_date": "2019-04-16", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2024-05-01", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03928353" }, { "nct_id": "NCT04541225", "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-12-08", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 12, "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541225" }, { "nct_id": "NCT00629720", "title": "Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Neurogenic" ], "interventions": [ { "name": "alfuzosin (SL770499)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "2 Years to 16 Years" }, "enrollment_count": 29, "start_date": "2006-07", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2009-12-15", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 1, "location_summary": "Malvern, Pennsylvania", "locations": [ { "city": "Malvern", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00629720" }, { "nct_id": "NCT00059462", "title": "Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Interleukin-2 SA", "type": "DRUG" }, { "name": "HAART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2002-12", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Davis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00059462" }, { "nct_id": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "VIP152 (BAY 1251152)", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 30 mg", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-02-10", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635672" }, { "nct_id": "NCT05775406", "title": "Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Malignancies", "Acute Lymphocytic Leukemia", "Lymphomas", "Advanced Solid Tumors" ], "interventions": [ { "name": "KT-253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kymera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2023-05-15", "completion_date": "2024-12-18", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Sacramento, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775406" }, { "nct_id": "NCT07423598", "title": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD0780", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2026-02-24", "completion_date": "2026-06-29", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07423598" }, { "nct_id": "NCT07115043", "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma (Skin)", "Renal Cell Carcinoma", "Merkel Cell Carcinoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer/Gastroesophageal Junction Cancer", "High Grade Serous Ovarian Carcinoma" ], "interventions": [ { "name": "AZD6750", "type": "DRUG" }, { "name": "rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-07-29", "completion_date": "2029-10-02", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 6, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115043" }, { "nct_id": "NCT02319369", "title": "Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Milademetan", "type": "DRUG" }, { "name": "AZA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2014-11-25", "completion_date": "2020-08-21", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-09T06:03:44.155Z", "location_count": 5, "location_summary": "Duarte, California • San Francisco, California • Fairway, Kansas + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319369" } ] }